Some clinics pivoted to recommending FDA-approved alternatives for weight management, including GLP-1 receptor agonists such as semaglutide (Wegovy) and tirzepatide (Zepbound), both of which have extensive Phase III data and FDA-approved labels
Common Side Effects: Nausea and Vomiting : Frequently occurs when starting semaglutide or increasing the dose Diarrhea: Common during the initial phase of treatment Constipation : Affects some patients during treatment Abdominal Pain : This may occur, often mild to moderate Headache : This can occur, especially at the start of treatment Fatigue : Ensure sufficient rest and a balanced diet
Many programs advertise a starting-dose price, then bill more as you titrate up over months two through five
As a dual agonist, tirzepatide interacts with both GIP and GLP-1 receptors, leading to a series of physiological responses that aid in weight management and blood sugar control
For the assay, 5000 cells in 200 L media per well are seeded in a 96 well plate